KTTAW Stock Financials: Financial Performance and Reports

Period	FY-2023	FY-2022	FY-2021	FY-2020
Period Ended	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Operating Revenue	$0.00	$486,559.00	$15,062.00	$0.00
Cost of Revenue	$648,454.00	$113,195.00	$17,275.00	$0.00
Gross Profit	-$648,454.00	$373,364.00	-$2,213.00	$0.00
Gross Profit Ratio	0	0.77	-0.15	0
Research and Development Expenses	$8.10 M	$2.67 M	$0.00	$0.00
General & Administrative Expenses	$7.88 B	$9.92 M	$0.00	$0.00
Selling & Marketing Expenses	-$7.87 B	$2.60 M	$0.00	$0.00
Selling, General & Administrative Expenses	$7.23 M	$12.52 M	$4.51 M	$40,984.00
Other Expenses	$0.00	$44,723.00	$0.00	$0.00
Operating Expenses	$15.33 M	$15.19 M	$4.51 M	$40,984.00
Cost And Expenses	$15.98 M	$15.30 M	$4.52 M	$40,984.00
Interest Income	$0.00	$102.00	$508.00	$0.00
Interest Expense	$0.00	$102.00	$508.00	$0.00
Depreciation & Amortization	$648,454.00	$77,097.00	$1,379.00	$61,476.00
EBITDA	-$15.33 M	-$14.74 M	-$4.51 M	-$40,980.00
EBITDA Ratio	0	-30.29	-299.17	0
Operating Income	-$15.98 M	-$14.82 M	-$4.51 M	-$40,980.00
Operating Income Ratio	0	-30.45	-299.26	0
Total Other Income/Expenses Net	$471,612.00	$879,869.00	$2.33 M	-$4.00
Income Before Tax	-$15.51 M	-$13.94 M	-$2.17 M	-$40,984.00
Income Before Tax Ratio	0	-28.64	-144.3	0
Income Tax Expense	$453.91 M	-$879,971.00	$508.00	-$61,476.00
Net Income	-$15.96 M	-$13.06 M	-$2.17 M	-$40,984.00
Net Income Ratio	0	-26.83	-144.34	0
EPS	-13.01	-10.34	-1.89	-0.0595
EPS Diluted	-13.01	-10.34	-1.89	-0.0595
Weighted Average Shares Out	$1.23 M	$1.26 M	$1.15 M	$688,918.00
Weighted Average Shares Out Diluted	$1.23 M	$1.26 M	$1.15 M	$688,918.00
Link

Pasithea Therapeutics Corp. (KTTAW) Financials